Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis
暂无分享,去创建一个
F. Saad | A. Briganti | S. Shariat | P. Karakiewicz | F. Chun | A. Kapoor | A. Lalani | M. Wenzel | Z. Tian | L. Nocera | Aly-Khan A. Lalani
[1] F. Saad,et al. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis , 2021, Prostate Cancer and Prostatic Diseases.
[2] F. Saad,et al. Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis. , 2021, European urology focus.
[3] C. Porta,et al. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. , 2021, The New England journal of medicine.
[4] C. Porta,et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. , 2021, The New England journal of medicine.
[5] C. Porta,et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial , 2020, ESMO Open.
[6] T. Powles,et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. , 2020, The Lancet. Oncology.
[7] M. Murad,et al. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis. , 2020, JAMA oncology.
[8] M. Burotto,et al. 711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy , 2020 .
[9] M. Burotto,et al. 696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial , 2020 .
[10] Kenya Yamaguchi,et al. Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC. , 2020, Clinical genitourinary cancer.
[11] M. Grimm,et al. New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies , 2020, Journal of clinical medicine.
[12] N. Agarwal,et al. First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. , 2019, European urology oncology.
[13] C. Porta,et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. , 2019, The Lancet. Oncology.
[14] C. Porta,et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial , 2019, The Lancet.
[15] T. Powles,et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.
[16] R. Motzer,et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.
[17] S. Boorjian,et al. First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. , 2018, European urology.
[18] S. Sleijfer,et al. Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial , 2017, JAMA oncology.
[19] T. Choueiri,et al. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] N. Vogelzang,et al. Axitinib Versus Sorafenib in First‐Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial , 2017, Clinical genitourinary cancer.
[21] M. Staehler,et al. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer. , 2015, European urology.
[22] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[23] R. Motzer,et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Reeves,et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.
[25] Nicky J Welton,et al. Automating network meta‐analysis , 2012, Research synthesis methods.
[26] R. Motzer,et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial , 2011, The Lancet.
[27] Georgia Salanti,et al. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. , 2011, Journal of clinical epidemiology.
[28] Neil Hawkins,et al. Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: A tutorial , 2010, BMC medical research methodology.
[29] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2009, Journal of clinical epidemiology.
[30] Deborah M Caldwell,et al. Simultaneous comparison of multiple treatments: combining direct and indirect evidence , 2005, BMJ : British Medical Journal.